35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Influenza and Tdap Vaccination Coverage Among Pregnant Women — United States, April 2020

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Vaccination of pregnant women with influenza vaccine and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) can decrease the risk for influenza and pertussis among pregnant women and their infants. The Advisory Committee on Immunization Practices (ACIP) recommends that all women who are or might be pregnant during the influenza season receive influenza vaccine, which can be administered at any time during pregnancy ( 1 ). ACIP also recommends that women receive Tdap during each pregnancy, preferably during the early part of gestational weeks 27–36 ( 2 , 3 ). Despite these recommendations, vaccination coverage among pregnant women has been found to be suboptimal with racial/ethnic disparities persisting ( 4 – 6 ). To assess influenza and Tdap vaccination coverage among women pregnant during the 2019–20 influenza season, CDC analyzed data from an Internet panel survey conducted during April 2020. Among 1,841 survey respondents who were pregnant anytime during October 2019–January 2020, 61.2% reported receiving influenza vaccine before or during their pregnancy, an increase of 7.5 percentage points compared with the rate during the 2018–19 season. Among 463 respondents who had a live birth by their survey date, 56.6% reported receiving Tdap during pregnancy, similar to the 2018–19 season ( 4 ). Vaccination coverage was highest among women who reported receiving a provider offer or referral for vaccination (influenza = 75.2%; Tdap = 72.7%). Compared with the 2018–19 season, increases in influenza vaccination coverage were observed during the 2019–20 season for non-Hispanic Black (Black) women (14.7 percentage points, to 52.7%), Hispanic women (9.9 percentage points, to 67.2%), and women of other non-Hispanic (other) races (7.9 percentage points, to 69.6%), and did not change for non-Hispanic White (White) women (60.6%). As in the 2018–19 season, Hispanic and Black women had the lowest Tdap vaccination coverage (35.8% and 38.8%, respectively), compared with White women (65.5%) and women of other races (54.0%); in addition, a decrease in Tdap vaccination coverage was observed among Hispanic women in 2019–20 compared with the previous season. Racial/ethnic disparities in influenza vaccination coverage decreased but persisted, even among women who received a provider offer or referral for vaccination. Consistent provider offers or referrals, in combination with conversations culturally and linguistically tailored for patients of all races/ethnicities, could increase vaccination coverage among pregnant women in all racial/ethnic groups and reduce disparities in coverage. An Internet panel* survey was conducted to assess end-of-season influenza and Tdap vaccination coverage estimates among women pregnant during the 2019–20 influenza season; the methods have been previously described ( 5 ). The survey was conducted during April 2–April 14, 2020, among women aged 18–49 years who reported being pregnant anytime since August 1, 2019, through the date of the survey. Among 18,314 women who were screened, 2,515 were eligible, and of these, 2,268 completed the survey (cooperation rate †  = 90.2%). Data were weighted to reflect the age, race/ethnicity, and geographic distribution of the total U.S. population of pregnant women ( 5 ). Analysis of influenza vaccination coverage was limited to 1,841 women pregnant anytime during October 2019–January 2020. A woman was considered to have been vaccinated against influenza if she reported having received 1 dose of influenza vaccine (before or during her most recent pregnancy) since July 1, 2019. To accommodate the optimal timing for Tdap vaccination during 27–36 weeks’ gestation, analysis of Tdap coverage was limited to women pregnant anytime since August 1, 2019, who had a live birth by their survey date. A woman was considered to have received Tdap if she reported receiving 1 dose of Tdap vaccine during her most recent pregnancy. Among 532 women with a recent live birth, 69 (12.9%) were excluded because they did not know whether they had ever received Tdap (10.3%) or whether they received it during their pregnancy (2.6%), leaving a final analytic sample of 463. The proportion of pregnant women who received both recommended maternal vaccines (i.e., full vaccination) was assessed among 462 women (one respondent reported Tdap but not influenza vaccination status). A difference was noted as an increase or decrease when a percentage-point difference of ≥5 was found between any values being compared. § SAS-callable SUDAAN software (version 11.0.1; RTI International) was used to conduct all analyses. Among 1,841 pregnant women, 61.2% reported receiving 1 dose of influenza vaccine since July 1, 2019, an increase of 7.5 percentage points compared with 53.7% reported for the 2018–19 influenza season; Tdap coverage was 56.6% among women with a recent live birth, similar to that reported for 2018–19 (54.9%) (Table 1) (Figure). Full vaccination was reported by 40.3% of women with a recent live birth overall, but only among 23.0% of Black and 25.4% of Hispanic women. Influenza vaccination coverage was lowest among Black women (52.7%), and Tdap coverage was lowest among Black (38.8%) and Hispanic (35.8%) women. Vaccination coverage was highest among women who reported receiving a provider offer or referral for vaccination (75.2% for influenza and 72.7% for Tdap). Women who had 10 or more provider visits since July 1, 2019, were more likely to have received influenza vaccine (67.5%) than were those with one to five visits (50.6%). TABLE 1 Influenza and Tdap vaccination coverage among pregnant women, by selected characteristics — Internet panel survey, United States, April 2020 Characteristic Influenza* Tdap† Both vaccines (full vaccination) No. (weighted %) % (weighted) vaccinated No. (weighted %) % (weighted) vaccinated No. (weighted %) % (weighted) vaccinated Total 1,841 (100) 61.2 463 (100) 56.6 462 (100) 40.3 Age group (yrs) 18–24 631 (24.4) 54.6§ 88 (13.8) 53.4 87 (13.6) 30.6 25–34 861 (55.6) 62.5 253 (61.6) 60.0§ 253 (61.7) 44.4§ 35–49¶ 349 (20.0) 65.8 122 (24.6) 50.1 122 (24.7) 35.3 Race/Ethnicity** White, non-Hispanic¶ 890 (49.7) 60.6 302 (63.7) 65.5 301 (63.6) 46.0 Black, non-Hispanic 323 (19.7) 52.7§ 52 (13.9) 38.8§ 52 (14.0) 23.0§ Hispanic 436 (23.1) 67.2§ 60 (14.1) 35.8§ 60 (14.1) 25.4§ Other, non-Hispanic 192 (7.4) 69.6§ 49 (8.3) 54.0§ 49 (8.3) 51.0§ Education High school diploma or less 450 (23.4) 45.9§ 114 (24.3) 45.2§ 114 (24.4) 25.0§ Some college, no degree 287 (15.4) 50.9§ 72 (15.6) 54.4§ 72 (15.6) 40.2§ College degree (2- or 4-year) 708 (39.7) 68.3 188 (42.1) 62.7 188 (42.2) 47.0 More than college degree¶ 396 (21.4) 72.2 89 (18.0) 60.0 88 (17.8) 45.2 Marital status†† Married¶ 1,012 (57.4) 70.3 293 (62.6) 65.3 293 (62.7) 51.0 Unmarried 828 (42.6) 49.1§ 170 (37.4) 42.1§ 169 (37.3) 22.3§ Employment status§§ Working¶ 1,158 (64.5) 66.9 269 (58.6) 56.9 293 (58.7) 40.2 Not working 682 (35.5) 50.8§ 194 (41.4) 56.3 193 (41.3) 40.4 Poverty status ¶¶ At or above poverty¶ 1,431 (79.6) 64.8 366 (79.7) 59.4 366 (79.7) 43.1 Below poverty 395 (20.4) 47.8§ 96 (20.3) 46.3§ 96 (20.3) 29.2§ Area of residence*** Rural 262 (13.9) 56.8§ 92 (19.0) 60.9§ 91 (18.9) 42.9 Nonrural¶ 1,579 (86.1) 61.9 371 (81.0) 55.6 371 (81.1) 39.7 Region††† Northeast¶ 379 (18.1) 64.0 75 (13.1) 58.7 75 (13.1) 42.7 Midwest 370 (20.0) 59.5 95 (19.3) 68.8§ 95 (19.3) 46.8 South 753 (38.0) 59.6 181 (36.9) 50.0§ 180 (36.8) 34.6§ West 339 (23.8) 63.2 112 (30.8) 56.1 112 (30.8) 41.9 Prenatal insurance status§§§ Private/Military¶ 857 (48.7) 67.4 251 (55.2) 64.0 251 (55.3) 46.2 Public 882 (45.8) 56.3§ 189 (39.9) 49.4* 189 (40.0) 34.7§ Uninsured 102 (5.5) 47.9§ <30 (—¶¶¶) —¶¶¶ <30 (—¶¶¶) —¶¶¶ Provider recommendation/offer**** Offered or referred¶ 1,294 (71.4) 75.2 346 (74.6) 72.7 286 (62.1)†††† 57.8 Recommended, no offer or referral 132 (7.3) 50.2§ <30 (—¶¶¶) —¶¶¶ 140 (30.8) §§§§ 13.9§ No recommendation 388 (21.3) 20.6§ 95 (20.5) 1.9§ 34 (7.2) ¶¶¶¶ 0.0§ No. of provider visits since July 2019 None <30 (—¶¶¶) —¶¶¶ N/A N/A N/A N/A 1–5 439 (23.9) 50.6§ N/A N/A N/A N/A 6–10 725 (38.7) 63.3 N/A N/A N/A N/A >10¶ 652 (36.2) 67.5 N/A N/A N/A N/A High-risk condition for influenza***** Yes¶ 779 (48.0) 65.9 N/A N/A N/A N/A No 829 (52.0) 59.1§ N/A N/A N/A N/A Abbreviations: N/A = not applicable; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. * Women pregnant any time during October 2019–January 2020 were included in the analyses to assess influenza vaccination coverage for the 2019–20 season. Women who received an influenza vaccination since July 1, 2019, before or during their pregnancy were considered vaccinated. † Women pregnant any time since August 1, 2019, and who had a live birth were included in the analysis to assess Tdap coverage. Women who received a Tdap vaccination during their recent pregnancy were considered vaccinated. § ≥5 percentage-point difference compared with referent group. ¶ Referent group for comparison within subgroups. ** Race/ethnicity was self-reported. Women identified as Hispanic might be of any race. The “Other” race category included Asians, American Indians/Alaska Natives, Native Hawaiians or other Pacific Islanders, and women who selected “other” or multiple races. †† Excludes one woman who did not report marital status. §§ Women who were employed for wages and self-employed were categorized as working; those who were out of work, homemakers, students, retired, or unable to work were categorized as not working. ¶¶ Poverty status was defined based on the reported number of persons living in the household and annual household income, according to U.S. Census poverty thresholds. https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html. *** Rurality was defined using ZIP codes where >50% of the population resides in a nonmetropolitan county, a rural U.S. Census tract, or both, according to the Health Resources and Services Administration’s definition of rural population. https://www.hrsa.gov/rural-health/about-us/definition/index.html. ††† Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. §§§ Women pregnant on their survey date were asked about current insurance; women who had already delivered were asked about insurance “during your most recent pregnancy.” Women considered to have public insurance selected at least one of the following when asked what kind of medical insurance they had: Medicaid, Medicare, Indian Health Service, state-sponsored medical plan, or other government plan. Women considered to have private/military insurance selected private medical insurance and/or military medical insurance and did not select any type of public insurance. ¶¶¶ Estimates with sample size <30 are not reported. **** Excluded women who did not report having a provider visit since July 2019 (25) for the influenza vaccination coverage analysis; no women were excluded for the Tdap vaccination coverage analysis. †††† Received provider offer/referral for both influenza and Tdap vaccines. §§§§ Received a combination of provider offer/referral, recommendation with no referral, or no recommendation for influenza or Tdap vaccines that does not include receipt of offer/referral for both vaccines or no recommendation received for both vaccines. For example, the respondent might have received an offer/referral for influenza vaccine and a recommendation with no referral for Tdap). If information about provider recommendation for either vaccine was missing, then the respondent was excluded from the analysis (two). ¶¶¶¶ Did not receive a provider recommendation for influenza or Tdap vaccine. ***** Conditions other than pregnancy associated with increased risk for serious medical complications of influenza include chronic asthma, a lung condition other than asthma, a heart condition, diabetes, a kidney condition, a liver condition, obesity, or a weakened immune system caused by a chronic illness or by medicines taken for a chronic illness. Women who were missing information (233) were excluded from analysis. FIGURE Influenza* and Tdap † vaccination coverage among pregnant women, by race/ethnicity — Internet panel survey, United States, 2017–18 § through 2019–20 ¶ influenza seasons Abbreviation: Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. * Women pregnant any time during October 2019–January 2020 were included in the analyses to assess influenza vaccination coverage for the 2019–20 season. Women who received an influenza vaccination since July 1, 2019, before or during their pregnancy, were considered vaccinated. † Women pregnant any time since August 1, 2019, and had a live birth were included in the analysis to assess Tdap coverage. Women who received a Tdap vaccination during their recent pregnancy were considered vaccinated. § Kahn KE, Black CL, Ding H, et al. Influenza and Tdap vaccination coverage among pregnant women—United States, April 2018. MMWR Morb Mortal Wkly Rep 2018;67:1055–9. ¶ Lindley MC, Kahn KE, Bardenheier BH, et al. Vital signs: burden and prevention of influenza and pertussis among pregnant women and infants—United States. MMWR Morb Mortal Wkly Rep 2019;68:885–92. The figure consists of two bar graphs showing influenza and Tdap vaccination coverage among pregnant women, by race/ethnicity, in the United States during the 2017–18 through 2019–20 influenza seasons according to an Internet panel survey. Increases in influenza vaccination coverage were observed during 2019–20 for Black women (14.7 percentage points, to 52.7%), Hispanic women (9.9 percentage points, to 67.2%), and women of other races (7.9 percentage points, to 69.6%). Correspondingly, the difference in influenza vaccination coverage between White and Black women decreased from 19 to 8 percentage points from 2018–19 to 2019–20 (Figure). A decrease in Tdap coverage was observed among Hispanic women from 2018–2019 to 2019–2020. The proportion of women who reported receipt of a provider offer or referral for influenza vaccination was higher among Hispanic women (76.9%) than among White (69.5%) and Black (69.1%) women but was similar to that among women of other races (73.7%). Among women with an offer or referral, influenza vaccination coverage was lower among Black (66.7%) than among White (75.6%) and Hispanic (79.0%) women and women of other races (80.7%) (Table 2). Among women with an offer or referral and 10 or more provider visits, influenza vaccination coverage was 64.3% in Black and 80.5% in White women. Influenza vaccination coverage was similar among White (73.6%) and Black (72.7%) women with an offer or referral and a condition ¶ (other than pregnancy) that put them at high risk for severe complications from influenza, but among those without high-risk conditions, coverage was lower among Black (62.8%) than among White women (77.4%). TABLE 2 Influenza vaccination coverage among pregnant women* who reported a health care provider offer or referral for vaccination, by selected characteristics, stratified by race/ethnicity † — Internet panel survey, United States, April 2020 Characteristic All women White, non-Hispanic Black, non-Hispanic Hispanic Other, non-Hispanic No. (weighted %) % (weighted) vaccinated No. (weighted %) % (weighted) vaccinated No. (weighted %) % (weighted) vaccinated No. (weighted %) % (weighted) vaccinated No. (weighted %) % (weighted) vaccinated Total 1,294 (100) 75.2 613 (100) 75.6 216 (100) 66.7 329 (100) 79.0 136 (100) 80.7 Age group (yrs) 18–24 438 (24.1) 67.1§ 132 (21.4) 64.2§ 108 (29.9) 65.6 151 (29.0) 71.5§ 47 (11.2) 76.6 25–34 611 (55.8) 77.7 333 (57.9) 79.5 81 (52.4) 64.0 137 (52.4) 83.8§ 60 (61.6) 79.5 35–49 245 (20.1) 77.8 148 (20.7) 76.8 <30 (—**) —** 41 (18.7) 77.5 <30 (—**) —** Education High school diploma or less 273 (20.0) 64.2§ 130 (21.0) 57.1§ 52 (20.2) 55.4§ 75 (21.7) 81.3 <30 (—**) —** Some college, no degree 194 (15.2) 65.3§ 78 (13.5) 62.1§ 39 (19.1) 69.4 53 (15.2) 69.8§ <30 (—**) —** College degree (2- or 4-year) 521 (41.4) 81.0 251 (41.6) 84.6 86 (41.6) 69.9 123 (38.5) 80.9 61 (48.1) 85.4 More than college degree¶ 306 (23.4) 80.6 154 (23.9) 84.0 39 (19.1) 69.0 78 (24.5) 79.8 35 (27.8) 84.5 Marital status †† Married¶ 757 (61.2) 81.0 418 (68.0) 80.6 84 (43.9) 79.5 169 (57.4) 81.1 86 (73.4) 85.2 Unmarried 537 (38.8) 66.0§ 195 (32.0) 65.2§ 132 (56.1) 56.6§ 160 (42.6) 76.2 50 (26.6) 68.6§ Employment status §§ Working¶ 847 (67.3) 79.2 410 (66.1) 79.7 147 (72.8) 70.6 206 (65.5) 82.1 84 (66.8) 89.5 Not working 446 (32.7) 66.9§ 203 (33.9) 67.8§ 68 (27.2) 55.2§ 123 (34.5) 73.3§ 52 (33.2) 63.0§ Poverty status ¶¶ At or above poverty¶ 1032 (81.3) 78.3 511 (83.4) 80.0 150 (72.9) 69.5 258 (81.7) 79.7 113 (88.0) 82.3 Below poverty 253 (18.7) 62.1§ 100 (16.6) 53.5§ 63 (27.1) 59.4§ 68 (18.3) 77.2 <30 (—**) —** Area of residence*** Rural 174 (13.1) 72.2 105 (17.5) 70.3§ <30 (—**) —** <30 (—**) —** <30 (—**) —** Nonrural¶ 1,120 (86.9) 75.6 508 (82.5) 76.8 189 (88.5) 65.8 301 (93.0) 79.2 122 (91.6) 80.9 Region ††† Northeast¶ 276 (18.8) 78.2 154 (22.1) 77.3 37 (16.0) 71.4 71 (17.2) 84.6 <30 (—**) —** Midwest 255 (19.8) 72.3§ 142 (23.4) 71.6§ 39 (18.7) 62.0§ 50 (15.2) 79.7 <30 (—**) —** South 520 (37.3) 74.2 217 (33.2) 74.5 125 (53.6) 70.6 122 (34.0) 77.4§ 56 (34.0) 76.3 West 243 (24.1) 76.7 100 (21.3) 80.0 <30 (—**) —** 86 (33.5) 77.5§ 42 (41.8) 82.1 Prenatal insurance status§§§ Private/Military¶ 631(50.9) 79.8 359 (58.1) 82.1 80 (41.2) 68.6 119 (39.8) 80.1 73 (65.6) 83.0 Public 608 (44.9) 70.5§ 229 (37.8) 65.6§ 125 (54.3) 67.3 196 (56.1) 77.9 58 (31.4) 77.7§ Uninsured 55 (4.2) 70.1§ <30 (—**) —** <30 (—**) —** <30 (—**) —** <30 (—**) —** No. of provider visits since July 2019 1–5 257 (19.7) 70.2§ 111 (18.0) 65.5§ 36 (17.2) 61.8 77 (23.5) 80.5 33 (23.9) 74.1§ 6–10 522 (39.8) 76.2 248 (40.5) 75.2§ 89 (39.5) 71.4§ 133 (39.7) 80.8 52 (36.8) 79.2§ >10¶ 515 (40.5) 76.6 254 (41.4) 80.5 91 (43.4) 64.3 119 (36.8) 76.1 51 (39.4) 86.3 High-risk condition for influenza ¶¶¶ Yes¶ 606 (51.7) 76.8 254 (44.3) 73.6 112 (59.2) 72.7 183 (65.5) 82.5 57 (40.0) 86.2 No 546 (48.3) 75.8 314 (55.7) 77.4 74 (40.8) 62.8§ 92 (34.5) 81.2 66 (60.0) 78.9§ * Women pregnant any time during October 2019–January 2020 were included in the analyses to assess influenza vaccination coverage for the 2019–20 season. Women who received an influenza vaccination since July 1, 2019, before or during their pregnancy were considered vaccinated. † Race/ethnicity was self-reported. Women identified as Hispanic might be of any race. The “Other” race category included Asians, American Indians/Alaska Natives, Native Hawaiians or Other Pacific Islanders, and women who selected “other” or multiple races. § ≥5 percentage-point difference compared with referent group. ¶ Referent group for comparison within subgroups. ** Estimates with sample size <30 are not reported. †† Excludes one woman who did not report marital status. §§ Women who were employed for wages and self-employed were categorized as working; those who were out of work, homemakers, students, retired, or unable to work were categorized as not working. ¶¶ Poverty status was defined based on the reported number of persons living in the household and annual household income, according to U.S. Census poverty thresholds. https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html. *** Rurality was defined using ZIP codes where >50% of the population resides in a nonmetropolitan county, a rural U.S. Census tract, or both, according to the Health Resources and Services Administration’s definition of rural population. https://www.hrsa.gov/rural-health/about-us/definition/index.html. ††† Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
§§§ Women pregnant on their survey date were asked about current insurance; women who had already delivered were asked about insurance “during your most recent pregnancy.” Women considered to have public insurance selected at least one of the following when asked what kind of medical insurance they had: Medicaid, Medicare, Indian Health Service, state-sponsored medical plan, or other government plan. Women considered to have private/military insurance selected private medical insurance and/or military medical insurance and did not select any type of public insurance. ¶¶¶ Conditions other than pregnancy associated with increased risk for serious medical complications of influenza include chronic asthma, a lung condition other than asthma, a heart condition, diabetes, a kidney condition, a liver condition, obesity, or a weakened immune system caused by a chronic illness or by medicines taken for a chronic illness. Women who were missing information (142) were excluded from analysis. Receipt of a provider offer or referral for Tdap was lower among Black (55.7%) than among Hispanic women (66.6%), women of other races (71.3%), and White women (81.0%). Among those with a provider offer or referral for Tdap vaccination, Tdap coverage was lowest for Hispanic women (52.5%), followed by Black women (64.7%), women of other races (73.1%), and White women (77.5%). Discussion Findings from this survey indicate that approximately 40% of pregnant women do not receive influenza and Tdap vaccines, leaving themselves and their infants more vulnerable to influenza and pertussis infection, with potential serious complications including hospitalization and death ( 4 ). Although influenza vaccination coverage remains suboptimal, an increase in coverage was observed during 2019–20. The overall increase was driven by increased vaccination coverage among Black and Hispanic women and those of other races. Higher vaccination coverage was observed among women who received a provider offer or referral or a recommendation alone ( 4 ), indicating increased acceptance of vaccination overall. However, despite approximately 70% of Black and White women receiving a provider offer or referral for influenza vaccination, Black women were still less likely to be vaccinated than White women. Factors including negative attitudes and beliefs about vaccines, less knowledge about and access to vaccines, and a lack of trust in health care providers and vaccines has been shown to contribute to lower vaccination rates in Black adults ( 6 , 7 ). Provider offers or referrals for vaccination, in combination with culturally competent conversations with patients, could increase vaccination coverage among pregnant women in all racial/ethnic groups and reduce disparities ( 8 ). Approximately 20% of pregnant women reported not receiving a provider recommendation for vaccination. This circumstance might be partly attributable to differences in perception of a provider recommendation between patients and providers. One study indicated that providers might believe they are giving a recommendation for vaccination, but it might not be remembered by patients ( 9 ). Differences by patient race/ethnicity in reported vaccination offers might result from provider-patient communication problems or reflect deficits in quality of care provided to some minority patients ( 10 ). CDC has resources to assist providers in effectively communicating the importance of vaccination, such as sharing specific reasons that recommended vaccines are right for the patient and highlighting positive experiences with vaccines (personal or clinical).** In addition, the American College of Obstetricians and Gynecologists has an immunization toolkit †† that includes communication strategies for providers. The findings in this report are subject to at least three limitations ( 5 ). First, this was a nonprobability sample, and results might not be generalizable to all pregnant women in the United States. Second, vaccination status was self-reported and might be subject to recall or social desirability bias. Finally, Tdap coverage estimates are subject to uncertainty, given the small sample size and exclusion of 12.9% of women with unknown Tdap vaccination status. Despite these limitations, Internet panel surveys are a useful assessment tool for timely evaluation of routine maternal vaccination coverage. Despite ACIP recommendations and an increase of approximately 12 percentage points in influenza vaccination since the 2017–18 season, maternal vaccination with influenza and Tdap vaccines is suboptimal, and missed opportunities to vaccinate are common. Although racial/ethnic disparities in vaccination persist, the magnitude in coverage differences were reduced in the 2019–20 influenza season as a result of increased vaccination coverage in Black, Hispanic, and other race women. Increases or decreases in vaccination coverage observed in this survey should be compared with information from other data sources and additional survey years. Racial disparities in vaccination coverage could decrease further with consistent provider offers or referrals for vaccination, in combination with culturally competent conversations with patients §§ ( 8 , 9 ). Summary What is already known about this topic? Maternal vaccination with influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines can decrease the risk for severe influenza and pertussis among pregnant women and their infants; racial/ethnic coverage disparities exist. What is added by this report? During 2019–20, 61.2% of pregnant women received influenza vaccination, 56.6% received Tdap during pregnancy, and 40.3% received both vaccines. Influenza vaccination coverage among Black and Hispanic women increased, yet disparities persisted; Tdap vaccination increased among Black women but decreased in Hispanic women compared with 2018–19. What are the implications for public health practice? Additional interventions to encourage consistent provider offers or referrals for influenza and Tdap vaccination and culturally competent conversations with patients are needed to address racial disparities in maternal vaccination.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season

          Summary This report updates the 2019–20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020–21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations. Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24, 2020. Primary updates to this report include the following two items. First, the composition of 2020–21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged ≥65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture–based IIV4 (ccIIV4) or RIV4. The 2020–21 influenza season will coincide with the continued or recurrent circulation of SARS-CoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html. This report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the 2020–21 season in the United States. A brief summary of the recommendations and a link to the most recent Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration (FDA)–licensed indications. Updates and other information are available from CDC’s influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

            Summary This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of tetanus, diphtheria, and pertussis in the United States. As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations and replaces all previously published reports and policy notes; it is intended for use by clinicians and public health providers as a resource. ACIP recommends routine vaccination for tetanus, diphtheria, and pertussis. Infants and young children are recommended to receive a 5-dose series of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines, with one adolescent booster dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Adults who have never received Tdap also are recommended to receive a booster dose of Tdap. Women are recommended to receive a dose of Tdap during each pregnancy, which should be administered from 27 through 36 weeks’ gestation, regardless of previous receipt of Tdap. After receipt of Tdap, adolescents and adults are recommended to receive a booster tetanus and diphtheria toxoids (Td) vaccine every 10 years to assure ongoing protection against tetanus and diphtheria.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019

              Introduction Since 2005, a single dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine has been recommended by the Advisory Committee on Immunization Practices (ACIP) for adolescents and adults ( 1 , 2 ). After receipt of Tdap, booster doses of tetanus and diphtheria toxoids (Td) vaccine are recommended every 10 years or when indicated for wound management. During the October 2019 meeting of ACIP, the organization updated its recommendations to allow use of either Td or Tdap where previously only Td was recommended. These situations include decennial Td booster doses, tetanus prophylaxis when indicated for wound management in persons who had previously received Tdap, and for multiple doses in the catch-up immunization schedule for persons aged ≥7 years with incomplete or unknown vaccination history. Allowing either Tdap or Td to be used in situations where Td only was previously recommended increases provider point-of-care flexibility. This report updates ACIP recommendations and guidance regarding the use of Tdap vaccines ( 3 ). Background Two Tdap vaccines are licensed for use in the United States. Boostrix (GlaxoSmithKline) is approved for a single dose in persons aged ≥10 years; Adacel (Sanofi Pasteur) is approved for persons aged 10–64 years. Since 2005, a single booster dose of Tdap has been recommended for children and adolescents aged 11–18 years and adults aged 19–64 years ( 1 , 2 ) to increase protection against tetanus, diphtheria, and pertussis. Booster doses of Td have been recommended every 10 years (decennial vaccination) to ensure continued protection against tetanus and diphtheria. These recommendations were expanded to include a single dose of Tdap for adults aged ≥65 years in 2012 (although only one Tdap product is approved for use in persons aged ≥65 years, either vaccine administered to a person aged ≥65 years is considered valid) ( 4 ). Pregnant women are recommended to receive a dose of Tdap during each pregnancy to prevent pertussis in infants too young for routine vaccination (off-label use*) ( 3 ). If a tetanus toxoid–containing vaccine is indicated for wound management, Td has been recommended for nonpregnant persons aged ≥7 years who had previously received Tdap. For pregnant women, Tdap is recommended in this setting. For previously unvaccinated persons aged ≥7 years, a 3-dose catch-up immunization schedule included only 1 dose of Tdap, preferably as the first dose in the series (off-label use in children aged 7–9 years), and 2 subsequent Td doses at specified intervals ( 5 ). No further doses of Tdap were routinely recommended, with two exceptions: pregnant women should receive Tdap during each pregnancy (off-label use), and children aged 7–10 years who received Tdap as part of the catch-up schedule were recommended to receive the routine adolescent Tdap booster dose at age 11–12 years ( 1 , 2 ). In 2010, ACIP evaluated the safety of administering Tdap at intervals 1 Tdap dose in the catch-up immunization schedule, the work group also considered published and unpublished safety data on receipt of >1 Tdap dose within a 12-month period in both pregnant women and nonpregnant adolescents and adults. Data from public sector orders (CDC, unpublished data, 2019), commercial insurance claims (Truven Health Analytics, unpublished data, 2019), and a published study from the Vaccine Safety Datalink (VSD) ( 29 ) were analyzed to assess stakeholders’ values attributed to perceived benefits and harms, acceptability, and implementation considerations regarding use of Tdap in place of Td. Summaries of evidence, including the evidence to recommendations framework (https://www.cdc.gov/vaccines/acip/recs/grade/tdap-etr.html) and assessment of programmatic considerations, were presented to ACIP at the October 2018, June 2019, and October 2019 meetings. Proposed recommendations were presented to the committee at the October 2019 meeting, and, after a public comment period, were approved by the voting members as follows: either Td or Tdap should be allowed for use in situations where only Td is currently recommended for the decennial Td booster, tetanus prophylaxis for wound management, and catch-up vaccination, including in pregnant women (14 voted in favor, and none opposed). Summary of Key Findings Safety and immunogenicity. Two clinical trials found no increased risk for adverse events among adults who received Tdap, compared with those who received Td 10 years after receipt of the initial Tdap dose ( 30 , 31 ). In addition, the proportion of persons with seroprotective levels of antibodies to tetanus and diphtheria was similar in the Tdap and Td groups. Another clinical trial compared adults receiving a second dose of Tdap 9 years after their initial Tdap dose with adults receiving Tdap for the first time as a control group ( 32 ). Solicited adverse events, the most frequent of which were injection site pain, fatigue, and headache, were higher in the groups receiving a second dose of Tdap. Grade 3 adverse events, defined in this study as redness and swelling with diameter >50 mm, pain, headaches, fatigue, gastrointestinal symptoms preventing normal activity, and fever with temperature >104°F(40°C), were similar in both groups. A retrospective VSD study identified 68,915 adolescents and adults who had received an initial dose of Tdap and then received another Td-containing vaccine, either a second Tdap (61,394, 89%) or Td (7,521, 11%). There was no statistically significant increase in medical visits for cellulitis, limb swelling, pain in limb, seizure, cranial nerve disorders, paralytic syndromes, encephalopathy, encephalitis, or meningitis among those who received a subsequent dose of Tdap compared with those who received Td ( 29 ). Data on the use of >1 Tdap dose in the catch-up immunization schedule are limited. One double-blind, randomized controlled clinical trial enrolled 460 adults aged ≥40 years who had not received a diphtheria or tetanus vaccination for ≥20 years or who had an unknown vaccination history. Subjects were randomized to receive either 3 doses of a Tdap formulation; 1 Tdap-inactivated polio vaccine combination dose, which is not licensed in the United States, followed by 2 Td doses; or 3 Td doses at 0, 1, and 6 months. There was no significant difference in adverse events for subjects receiving 3 Tdap doses, compared with those receiving 3 Td doses, and no significant differences in diphtheria and tetanus seroprotection rates among the three groups ( 33 ). An analysis of data collected as part of a published VSD retrospective study ( 29 ) identified 13,599 persons who had received an initial dose of Tdap and then received another Td-containing vaccine within 12 months of the previous Tdap dose, either a second Tdap (11,687, 86%) or Td (1,912, 16%). There was no elevated risk for medical visits for adverse events among those who received a subsequent dose of Tdap compared with those who received Td (CDC/VSD, unpublished data, 2019). Among 34,804 reports to the Vaccine Adverse Event Reporting System (VAERS) ( 34 ) following receipt of Tdap in nonpregnant and pregnant persons of all ages during January 1, 1990–June 30, 2019, 88 (0.3%) persons had received multiple Tdap doses spaced ≤12 months apart. Among this small group of reports, 21 (24%) were associated with adverse events, the most frequent of which was injection site reactions (8, 38%) (CDC, unpublished data, 2019). There are no published data comparing rates of adverse events among pregnant women who received multiple doses of Tdap during a single pregnancy with those who received a single Tdap dose and additional Td doses for catch-up vaccination. A cohort study examining reactogenicity of Tdap in pregnant women included only eight study participants who received >1 Tdap dose within a 12-month period; none experienced severe reactions or fever ( 35 ). A VSD study examining safety of Tdap during pregnancy identified 187 women who had received >1 Tdap dose during a single pregnancy among 633,542 singleton pregnancies screened for potential study inclusion ( 36 ). Although these 187 women were excluded from the published study, the authors found similar rates of adverse birth outcomes (i.e., small for gestational age, preterm delivery, and low birthweight) in these women compared with women who had received a single Tdap dose in pregnancy (29,155). Among these 187 women who received >1 Tdap dose during pregnancy, one had a medically attended acute adverse event, which was diagnosed as limb pain and swelling 7 days after vaccination. One woman received 3 Tdap doses during a single pregnancy; she did not experience any adverse events, and her baby was born at term (CDC, unpublished data, 2019). Acceptability to patients and providers. Analysis of commercial insurance claims indicated that Tdap claims were 12 times as high as Td claims in adults aged 19–64 years during 2017 (Truven Health Analytics, unpublished data, 2019). In the same year, there were approximately 10 times the number of Tdap doses (441,075) as Td doses (41,881) ordered by providers for adults as public sector purchases (CDC, unpublished data, 2019). These data, in addition to the one published VSD study ( 29 ) documented that Tdap was widely used in place of Td by clinicians in the United States and suggested acceptability to both patients and health care providers. Health impact and economic considerations. Tdap costs more than Td ( 37 ). The population-level effectiveness and economic impact of replacing Td with Tdap has been modeled and previously reviewed by ACIP ( 24 ). However, this analysis and an updated model of the economic impact of substituting Tdap for the decennial Td booster demonstrated that estimates of cost effectiveness are dependent on values for parameters with a high degree of uncertainty, including pertussis incidence, illness severity, initial vaccine effectiveness, duration of protection, and the impact of Tdap on herd protection ( 38 ). Coupling such uncertainty with the evidence for notable widespread use of Tdap in place of Td, programmatic issues were the main consideration in the decision-making process. Rationale for Recommendations In 2013, ACIP did not support a general recommendation for a routine second dose of Tdap; the rationale was described in previously published guidance ( 3 ). In 2019, ACIP again concluded that in light of the higher cost of Tdap relative to Td and uncertainty about the impact that receipt of multiple Tdap doses would have on pertussis control and transmission, there continues to be insufficient evidence to preferentially recommend that Tdap replace Td. However, given the reassuring safety profile and evidence of widespread use of Tdap in place of Td, to allow providers more flexibility, either Tdap or Td was recommended for use in situations when previously only Td was recommended. ACIP recommends that either Td or Tdap be used for the decennial Td booster, tetanus prophylaxis for wound management, and for additional required doses in the catch-up immunization schedule if a person has received at least 1 Tdap dose. General Recommendations Persons aged 11–18 years. These persons should receive a single dose of Tdap, preferably at a preventive care visit at age 11–12 years. To ensure continued protection against tetanus and diphtheria, 1 booster dose of either Td or Tdap should be administered every 10 years throughout life. Persons aged ≥19 years. Regardless of the interval since their last tetanus or diphtheria toxoid–containing vaccine, persons aged ≥19 years who have never received a dose of Tdap should receive 1 dose of Tdap. To ensure continued protection against tetanus and diphtheria, booster doses of either Td or Tdap should be administered every 10 years throughout life. Pregnant women. No change has been made to the recommendations for routine Tdap immunization during pregnancy. Pregnant women should receive 1 dose of Tdap during each pregnancy, irrespective of their history of receiving the vaccine. Tdap should be administered at 27–36 weeks’ gestation, preferably during the earlier part of this period, although it may be administered at any time during pregnancy ( 3 , 5 ). Tetanus Prophylaxis for Wound Management Recommendations A tetanus toxoid–containing vaccine is indicated for wound management when >5 years have passed since the last tetanus toxoid–containing vaccine dose. If a tetanus toxoid–containing vaccine is indicated for persons aged ≥11 years, Tdap is preferred for persons who have not previously received Tdap or whose Tdap history is unknown. If a tetanus toxoid–containing vaccine is indicated for a pregnant woman, Tdap should be used. For nonpregnant persons with documentation of previous Tdap vaccination, either Td or Tdap may be used if a tetanus toxoid–containing vaccine is indicated. Complete information on tetanus prophylaxis and the use of tetanus immunoglobulin when indicated for wound management is available at https://www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm. Catch-Up Immunization Recommendations Persons aged 7–18 years. If persons aged 7–18 years have never been vaccinated against pertussis, tetanus, or diphtheria, these persons should receive a series of three tetanus and diphtheria toxoid–containing vaccines, which includes at least 1 Tdap dose. The preferred schedule is 1 dose of Tdap, followed by 1 dose of either Td or Tdap ≥4 weeks afterward, and 1 dose of either Td or Tdap 6–12 months later. Persons aged 7–18 years who are not fully immunized against tetanus and diphtheria should receive 1 dose of Tdap, preferably as the first dose in the catch-up series; if additional tetanus toxoid–containing doses are required, either Td or Tdap may be used. The vaccination series does not need to be restarted for those with incomplete DTaP history, regardless of the time that has elapsed between doses. The catch-up schedule and minimum intervals between doses are available at https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html. Persons aged ≥19 years. If persons aged ≥19 years have never been vaccinated against pertussis, tetanus, or diphtheria, these persons should receive a series of three tetanus and diphtheria toxoid–containing vaccines, which includes at least 1 Tdap dose. The preferred schedule is 1 dose of Tdap, followed by 1 dose of either Td or Tdap at least 4 weeks afterward, and 1 dose of either Td or Tdap 6–12 months later. Persons aged ≥19 years who are not fully immunized against tetanus and diphtheria should receive 1 dose of Tdap, preferably as the first dose in the catch-up series; if additional tetanus toxoid–containing doses are required, either Td or Tdap may be used. Prevention of Neonatal and Obstetric Tetanus Pregnant women who have completed the childhood immunization schedule and were last vaccinated >10 years previously should receive a booster dose of tetanus toxoid–containing vaccine to prevent neonatal tetanus. The risk for neonatal tetanus is minimal if a previously unvaccinated woman has received at least 2 properly spaced doses of a tetanus toxoid–containing vaccine during pregnancy; at least 1 of the doses administered during pregnancy should be Tdap, administered according to published guidance ( 3 ). If >1 dose is needed, either Td or Tdap may be used. The 3-dose primary series should be completed at the recommended intervals. CDC Guidance Catch-up immunization. For persons aged 7–9 years who receive a dose of Tdap as part of the catch-up series, an adolescent Tdap dose should be administered at age 11–12 years. If a Tdap dose is administered at age ≥10 years, the Tdap dose may count as the adolescent Tdap dose. Inadvertent Administration Persons aged ≥7 years. DTaP is not indicated for persons aged ≥7 years. If DTaP is administered inadvertently to a fully vaccinated † child aged 7–9 years, an adolescent Tdap dose should be administered at age 11–12 years. If DTaP is administered inadvertently to an undervaccinated child aged 7–9 years, this dose should count as the Tdap dose of the catch-up series, and the child should receive an adolescent Tdap dose at age 11–12 years. If DTaP is administered inadvertently to a person aged ≥10 years, this dose should count as the adolescent Tdap dose routinely administered at age 11–12 years. Fully vaccinated children aged 7–10 years. If a fully vaccinated child aged 7–9 years receives Tdap, the Tdap dose should not be counted as valid. The adolescent Tdap dose should be administered as recommended when this child is aged 11–12 years. The preferred age at administration for the adolescent Tdap dose is 11–12 years. However, if Tdap is administered at age 10 years, the Tdap dose may count as the adolescent Tdap dose. Off-Label Use of Vaccine Off-label indications based on age and pregnancy status have not changed (Table). New off-label indications for Adacel would include any additional routine or catch-up Td dose beyond a second dose administered ≥8 years after an initial Tdap dose, if not given for wound prophylaxis within the specified guidance. Any additional doses of Boostrix administered beyond the single licensed dose are considered off-label. The work group did not find any reason to distinguish between these two products in making its recommendations. TABLE Food and Drug Administration (FDA)–approved and off-label recommendations for licensed tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) products — United States, 2019 Licensed Tdap product FDA-approved indications for use and administration Off-label uses Decennial Td booster Tetanus prophylaxis for wound management Catch-up immunization,* including during pregnancy† Adacel §    Age: 10–64 years    Age: ≥65 years    Age: 1 Tdap dose    Tetanus prophylaxis if ≥5 years have elapsed since the last tetanus-containing vaccine Boostrix §    Age: ≥10 years    Any dose if previously received Tdap    Age: 1 Tdap dose    Tetanus prophylaxis if no previous Tdap Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; Td = tetanus and reduced diphtheria toxoid. * Persons with incomplete or unknown vaccination history should receive a single dose of Tdap, preferably as the first dose of the 3-dose catch-up series; if additional tetanus toxoid–containing doses are needed, either Td or Tdap vaccine may be used. † Both Tdap vaccines may be administered during pregnancy with the same intervals and restrictions (vaccine specific) as would apply to a nonpregnant person. § Package inserts for indications and intervals for wound management are available at https://www.fda.gov/media/119862/download (Adacel) and https://www.fda.gov/media/124002/download (Boostrix). Contraindications and precautions. Contraindications and precautions are unchanged from previous recommendations ( 3 ). Reporting of vaccine adverse reactions. Adverse events occurring after administration of any vaccine should be reported to VAERS. Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (1-800-822-7967) or online (https://vaers.hhs.gov). Future Research and Monitoring Priorities ACIP will continue to review data on Td and Tdap as they become available, examine the necessity and frequency of booster doses for protection against tetanus and diphtheria, and consider any needed policy changes. As with all vaccines, CDC will use VAERS and VSD to monitor adverse events following immunization. Summary What is already known about this topic? Repeat doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine at 5- and 10-year intervals are safe and immunogenic. What is added by this report? ACIP recommendations have been updated to allow either tetanus and diphtheria toxoids (Td) vaccine or Tdap to be used for the decennial Td booster, tetanus prophylaxis for wound management, and for additional required doses in the catch-up immunization schedule if a person has received at least 1 Tdap dose. What are the implications for public health practice? Allowing either Tdap or Td to be used in situations where Td only was previously recommended increases provider point-of-care flexibility.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb Mortal Wkly Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                02 October 2020
                02 October 2020
                : 69
                : 39
                : 1391-1397
                Affiliations
                Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; Leidos, Atlanta, Georgia; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC; Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC; Abt Associates, Inc., Atlanta, Georgia.
                Author notes
                Corresponding author: Hilda Razzaghi, HRazzaghi@ 123456cdc.gov .
                Article
                mm6939a2
                10.15585/mmwr.mm6939a2
                7537555
                33001873
                80cca4c9-73e7-4fca-8a56-e2e2eb8c8ba3

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article